Using platelet function analysis to personalise anti-thrombotic drug therapies
| ISRCTN | ISRCTN67917825 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN67917825 |
| IRAS number | 357473 |
| Secondary identifying numbers | CPMS 69135 |
- Submission date
- 16/06/2025
- Registration date
- 16/06/2025
- Last edited
- 16/07/2025
- Recruitment status
- Not yet recruiting
- Overall study status
- Ongoing
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Platelets are tiny cells in our blood that help stop bleeding by forming clots when blood vessels are damaged. But sometimes, they form clots when they shouldn’t. This can block blood flow and cause serious problems like heart attacks and strokes. Medicines that reduce clotting can help, but they also increase the risk of dangerous bleeding. Right now, doctors don’t have a good way to know which patients will benefit from these medicines and which might be harmed. This study is testing a new way to measure how platelets behave, to help doctors make better decisions about treatment. The goal is to see how well this test works in people who’ve had a type of heart attack called a non-STEMI.
Who can participate?
Adults aged 18 or over who have been diagnosed with a non-STEMI heart attack.
What does the study involve?
Participants will have their platelet function tested three times:
-When they are admitted to hospital
-Around two months later (when they are likely taking two anti-clotting medicines)
-At 12 months (after one of the medicines has been stopped)
These tests will help researchers understand how platelets behave over time and how this relates to treatment.
What are the possible benefits and risks of participating?
Taking part may not directly benefit participants, but it could help improve treatment for future patients. The risks are low, but as with any blood test, there may be minor discomfort or bruising.
Where is the study run from?
University of Reading (UK)
When is the study starting and how long is it expected to run for?
June 2025 to August 2030.
Who is funding the study?
British Heart Foundation
Who is the main contact?
Jonathan Gibbins, j.m.gibbins@reading.ac.uk
Contact information
Public, Scientific, Principal Investigator
University of Reading, School of Biological Sciences, Health and Life Sciences Building
Reading
RG6 6EX
United Kingdom
 ORCID ID |
0000-0002-0372-5352 |
|---|---|
| Phone | +44 1183787082 |
| j.m.gibbins@reading.ac.uk |
Study information
| Study design | Single-centre longitudinal observational analysis of platelet function using Platelet Phenomic Analysis to refine its use for personalisation of anti-platelet therapy in patients diagnosed with non-STEMI myocardial infarction. |
|---|---|
| Primary study design | Observational |
| Secondary study design | Longitudinal study |
| Study setting(s) | Hospital |
| Study type | Diagnostic, Screening |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | PLatelet phenomics Analysis to guide patient Stratification and anti-platelet Medication In acute Coronary syndrome |
| Study acronym | PLASMIC |
| Study objectives | Platelet Phenomic Analysis can guide therapeutic choices for patients with acute coronary syndrome |
| Ethics approval(s) |
Submitted 09/06/2025, West Midlands - Edgbaston Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048137; edgbaston.rec@hra.nhs.uk), ref: 25/WM/0133 |
| Health condition(s) or problem(s) studied | Acute coronary syndrome: non-STEMI myocardial infarction |
| Intervention | Platelet phenomics analysis to be performed at admission, at approximately 2 months (when likely to be on dual anti-platelet therapy) and at 12 months following removal of second anti-platelet agent |
| Intervention type | Other |
| Primary outcome measure | Platelet phenomics analysis to assess impact of inherent platelet function capacity on responses to single and dual anti-platelet therapies at baseline, 2 months, 12 months |
| Secondary outcome measures | Pharmacogenomic analysis to determine impact on platelet function responses (measured by Platelet Phenomic Analysis) of different anti-platelet agents at baseline, 2 months, 12 months |
| Overall study start date | 16/06/2025 |
| Completion date | 31/08/2030 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 100 Years |
| Sex | Both |
| Target number of participants | 400 |
| Key inclusion criteria | Diagnosis of non-STEMI myocardial infarction |
| Key exclusion criteria | Patients already taking P2Y12 antagonists, pregnancy, active or recent malignancy, and renal, liver or other haematological pathologies |
| Date of first enrolment | 01/01/2026 |
| Date of final enrolment | 01/07/2028 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Craven Road
Reading
RG1 5AN
United Kingdom
Sponsor information
University/education
Whiteknights House, Whiteknights
Reading
RG6 6AH
England
United Kingdom
| Phone | +44 1183225111 |
|---|---|
| a.j.davy@reading.ac.uk | |
| Website | https://www.reading.ac.uk |
"ROR" |
https://ror.org/05v62cm79 |
Funders
Funder type
Charity
Private sector organisation / Trusts, charities, foundations (both public and private)
- Alternative name(s)
- the_bhf, The British Heart Foundation, BHF
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 31/08/2030 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | To be published in leading open-access academic journals. Press releases will be used for wider public engagement and education. Adoption of tests to be in collaboration with HaemAnalytica Ltd. |
| IPD sharing plan | Brief report aimed at participants will be available at the conclusion of the study. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. j.m.gibbins@reading.ac.uk (Jonathan Gibbins) Platelet function analysis – raw and processed using our open source and publicly available software. This will not make much sense without our prior analysis and will form the basis of our future patient stratification procedures. Thus the most helpful way to access with be via email and with our support. Data will be available from point of publication and will be available in perpetuity via UoReading research data repository. Likely to be helpful for other groups interest in patient stratification based on platelet function analysis using our analytical systems. Consent was obtained. No legal restrictions at this point, although if this forms the basis of new IP protection, this may slow down sharing. Protection of IP will be necessary to support commercialisation that will be essential for wide adoption in the longer term. |
Editorial Notes
16/07/2025: Internal review.
16/06/2025: Trial's existence confirmed by British Heart Foundation.
